TrialCancer medicine2021

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.

Michele Malagola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.